KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $790,593 | -27.1% | 24,799 | -8.1% | 0.00% | 0.0% |
| Q2 2023 | $1,084,137 | +31.8% | 26,982 | +40.0% | 0.00% | 0.0% |
| Q1 2023 | $822,873 | -1.5% | 19,271 | +10.8% | 0.00% | 0.0% |
| Q4 2022 | $835,212 | +123.3% | 17,393 | +74.9% | 0.00% | – |
| Q3 2022 | $374,000 | -4.8% | 9,947 | -30.0% | 0.00% | – |
| Q2 2022 | $393,000 | -16.9% | 14,215 | +63.1% | 0.00% | – |
| Q1 2022 | $473,000 | +3.3% | 8,715 | +11.5% | 0.00% | – |
| Q4 2021 | $458,000 | +38.0% | 7,819 | -6.7% | 0.00% | – |
| Q3 2021 | $332,000 | -6.7% | 8,379 | +0.1% | 0.00% | – |
| Q2 2021 | $356,000 | -7.8% | 8,367 | +33.2% | 0.00% | – |
| Q1 2021 | $386,000 | -64.0% | 6,281 | -58.7% | 0.00% | -100.0% |
| Q4 2020 | $1,073,000 | – | 15,213 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |